Vicore Pharma Holding AB (publ)

Healthcare · Biotechnology · Sweden

Last price 9.8 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 277.97M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III cl...